RNA has recently emerged as an important nanotechnology platform due to its extraordinary diversity in structure and function. Small interfering RNA (siRNA), showed significant potential in new molecular approaches to down-regulate specific gene expression in mammalian cells. In fact, targeted gene suppression by antisense DNA and siRNA has shown promising preclinical results, and/or is currently in clinical trials for a variety of diseases, including many forms of cancer (e.g., melanoma, neuroblastoma, and pancreatic adenocarcinoma), genetic disorders, and macular generation . Despite the high therapeutic potential of siRNA, its application for clinical medicine is still limited mainly due to the lack of appropriate delivery systems. In such a situation, the development of clinically suitable, safe, and effective drug-delivery biomaterials are required for the widespread use of siRNA therapeutics for disease treatment. Following such stringent rules and evaluation can be costly, so publishers charge from the users who access the information, but, it will obstruct research as young researchers can afford it. Alternatively, fees can be charged from the researcher who has made the research and it can be free to the user who is interested in research thus, increasing the popularity and reputation to scholar and enhancing knowledge to user. OMICS is one such organization which freely publishes online journals where quality information resides and students, academicians etc can improve their knowledge by freely accessing these journals. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals. Molecular Biology is one of the best online open access journals which publish original research, review, Short communication, and Case study in the field of Molecular Biology and its current research. It has world quality editorial board members in order to develop its standards.
Last date updated on July, 2014